Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICS-V: Saroglitazar Magnesium in Primary Biliary Cholangitis
NCT07216235Phase 3Recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Mar 2026
- Primary completion
- Nov 2032
- Countries
- 1
01
Overview
A Phase 3 trial of saroglitazar magnesium in primary biliary cholangitis (PBC), sponsored by Zydus Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
saroglitazar magnesium
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT07216235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216235.